Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | CPB1 | P15086 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5083074 | 1.00 | HTR2C (0.51) | HTR2CSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL15122669 | 0.91 | HTR2C (0.51) | HTR2CSMN1; SMN2NPC1RAB9AFKBP1A | |
| SCHEMBL15122671 | 0.91 | HTR2C (0.51) | HTR2CSMN1; SMN2NPC1RAB9AFKBP1A | |
| SCHEMBL31107806 | 0.91 | HTR2C (0.51) | HTR2CSMN1; SMN2NPC1RAB9AFKBP1A | |
| SCHEMBL464281 | 0.87 | HTR2C (0.52) | HTR2CSMN1; SMN2NPC1RAB9AGLA | |
| SCHEMBL873281 | 0.87 | HTR2C (0.52) | HTR2CSMN1; SMN2NPC1RAB9AGLA | |
| SCHEMBL6000873 | 0.87 | HTR2C (0.52) | HTR2CSMN1; SMN2NPC1RAB9AGLA | |
| SCHEMBL1448039 | 0.87 | HTR2C (0.48) | HTR2CSMN1; SMN2NPC1RAB9AFKBP1A | |
| SCHEMBL6691930 | 0.87 | HTR2C (0.48) | HTR2CSMN1; SMN2NPC1RAB9AFKBP1A | |
| SCHEMBL14814214 | 0.87 | HTR2C (0.48) | HTR2CSMN1; SMN2NPC1RAB9AFKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118574834-A | Fused tetracyclic compounds, compositions and uses thereof | 泰博生物科技股份有限公司 | 2024-08-30 | — | — | CN | disclosed |
| EP-3536685-B1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | PFIZER (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3536685-A1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | Pfizer Inc (US) | 2019-09-11 | — | — | EP | disclosed |
| US-8377872-B2 | Non-structural protein-3 (NS-3) protease inhibitors; viricides | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20080267916-A1 | CYCLIC P3 TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080267916-A1 | CYCLIC P3 TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, CTSC, PREP | HTR2C 3514/4885SMN1; SMN2 3560/4885NPC1 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.